AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 212 min read$ABT

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The announcement clarifies Abbott's strategic focus on higher‑growth medical devices and diagnostics, while shedding a low‑growth, litigation‑laden segment.

02

Market read

The spin‑off is a material corporate action for a large‑cap stock, driving immediate price movement and reshaping the company's growth profile.

03

What to watch

One‑time charges and regulatory approvals could delay the spin‑off, and the retained business still carries litigation risk from past formula recalls.

Relevance 7/10Novelty 9/10Timing: pre‑market today

Background

Abbott Laboratories (ABT) is a diversified healthcare company. The Nutrition unit includes brands like Similac, Pedialyte and Ensure.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott announced a tax‑free spin‑off of its Nutrition unit (~$8.5 B revenue) and shares fell >4% pre‑market.

Expected impact

downward pressure as investors price in the loss of the Nutrition business

Evidence & confidence

Spin‑offs of underperforming units typically trigger a sell‑off; the 4% pre‑market drop confirms market reaction.

Market effects

Sector

Nutrition/infant formula segment faces uncertainty; peers may see relative strength as Abbott refocuses on medical devices and diagnostics.

Regional

U.S. healthcare sector may see modest re‑rating; no immediate global effect.

Global

Limited to investors tracking large‑cap healthcare stocks.

Counterpoint

What could challenge this read

The spin‑off could unlock value if the new Nutrition company attracts a strategic buyer, potentially boosting Abbott's core valuation.

Key entities

  • company
    Abbott Laboratories

    US‑listed healthcare conglomerate executing the spin‑off.

  • executive
    Daniel Salvadori

    Leads the new Nutrition company post‑spin‑off.

Read at source← All news

StoryAbbott to spin off Nutrition unit into independent public company by end‑2027

Also covered by

6 outlets

Related articles

OCT 21
$ABTHigh

Abbott Laboratories Stock (ABT) Dips 2% on Spinoff Plans for Abbott Nutrition

Abbott Laboratories (ABT) fell 2.11% after announcing plans to spin off its nutrition unit, Abbott Nutrition, into a separate publicly traded company with $8.5B annual revenue. The spinoff, expected by 2027, will not impact 2026-2027 guidance. Abbott will retain $42B revenue, focusing on medical devices and diagnostics. Shareholders will receive Abbott Nutrition shares. Analysts rate ABT a Strong Buy with a $125.50 target.

tipranks.com2 min
OCT 21
$ABTHigh

Abbott Laboratories (ABT) Revises Growth Outlook, Plans Nutritio

Abbott Laboratories (ABT) lowered its full-year growth forecast and announced a spin-off of its nutrition business, causing a premarket decline. Despite this, the company reported Q3 revenues of $13.0 billion, a 14.5% YoY increase. ABT offers a 2.56% dividend yield, a payout ratio of 80%, and a GF Value of $135.69, suggesting modest undervaluation. Insider activity shows net selling, while 23 premium gurus hold ABT shares.

gurufocus.com2 min
OCT 21
$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Abbott Laboratories reported Q3 2026 sales of $13.01B (up from $11.37B YoY) and net income of $920M (down from $1.64B YoY). Nine-month sales reached $36.77B (up from $32.87B YoY), with net income of $2.93B (down from $4.75B YoY). The company's products include vascular devices, diagnostic systems, nutrition products, and medicines, with sales distributed globally.

marketscreener.com2 min
OCT 21
$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

SEC EDGAR 8-K3 min